Endocrinopathies occur in about 10% of patients who receive immune checkpoint inhibitors. Cleveland Clinic researchers review the them and look at principles of management.
New guidelines support oncologists in treating recurrent and metastatic head and neck cancers
A patient opts for a novel clinical trial and thrives with stage 4 colorectal cancer.
In May, the FDA approved atezolizumab in combination with bevacizumab for newly diagnosed patients with hepatocellular carcinoma.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Is checkpoint inhibitor-related polymyalgia rheumatica (PMR) distinct from the classic rheumatic disease, or does it represent new clinical variants with potentially different pathogenesis, clinical course and treatment responsiveness? Rheumatologist/immunologist Cassandra Calabrese, DO, discusses her research, which identified clinical features that are unusual in idiopathic PMR.
A common occurrence in the age of cancer immunotherapy, immune-related adverse events require multidisciplinary collaboration for investigation and optimal management. Drs. Cassandra and Leonard Calabrese discuss the ever-evolving field and the need for continuing education.
The goal of the tumor board is to discuss new and/or challenging cases of irAEs, review the extant literature and receive input on interprofessional management.
Checkpoint inhibitor therapy for cancer holds great potential for durable response rates, but immune-related adverse events may be its Achilles’ heel.